Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| GeneDx Holdings Corp.WGS · Entity 1634 | Director | June 18, 2026 | June 23, 2026 |
| Twist Bioscience CorpTWST · Entity 3619 | Director · Chief Executive Officer | October 05, 2026 | October 07, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
GeneDx Holdings Corp.
Report date June 18, 2026 · Filed June 23, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 24,852 |
Reported balance
After 2026-06-18 transaction · row 1
1 source rowRow 1 · 2026-06-18 · Exercise / conversion · Acquired 3,576 · Balance 24,852 F1: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 4,248 |
Reported balance
After 2026-06-18 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-18 · Grant · Acquired 4,248 · Balance 4,248 F1: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration. F2: The entire award shall vest on the earlier of the (i) date of the 2027 annual meeting of the Issuer's stockholders, or (ii) first anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer through the vesting date. These RSUs do not have an expiration date; they either vest or are cancelled prior to the vesting date. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-06-18 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-06-18 · Exercise / conversion · Disposed 3,576 · Balance 0 F1: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration. F3: The entire award vested or vests on the earlier of the: (i) date of the 2026 annual meeting of the Issuer's stockholders, or (ii) first anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer through the vesting date. These RSUs do not have an expiration date; they either vest or are cancelled prior to the vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration.
F2: The entire award shall vest on the earlier of the (i) date of the 2027 annual meeting of the Issuer's stockholders, or (ii) first anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer through the vesting date. These RSUs do not have an expiration date; they either vest or are cancelled prior to the vesting date.
F3: The entire award vested or vests on the earlier of the: (i) date of the 2026 annual meeting of the Issuer's stockholders, or (ii) first anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer through the vesting date. These RSUs do not have an expiration date; they either vest or are cancelled prior to the vesting date.
Twist Bioscience Corp
Report date October 05, 2026 · Filed October 07, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 562,760 |
Ending reported balance
After 2026-10-05 transaction · row 8
8 source rows · reconciled sequenceRow 1 · 2026-10-05 · Sale · Disposed 1,840 · Balance 565,468 F1: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on June 15, 2026. F2: Represents the weighted average sales price per share. The shares sold at prices ranging from $200 to $200.99 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Row 2 · 2026-10-05 · Sale · Disposed 481 · Balance 564,987 F1: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on June 15, 2026. F3: Represents the weighted average sales price per share. The shares sold at prices ranging from $201 to $201.99 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Row 3 · 2026-10-05 · Sale · Disposed 1,017 · Balance 563,970 F1: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on June 15, 2026. F4: Represents the weighted average sales price per share. The shares sold at prices ranging from $202 to $202.99 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Row 4 · 2026-10-05 · Sale · Disposed 432 · Balance 563,538 F1: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on June 15, 2026. F5: Represents the weighted average sales price per share. The shares sold at prices ranging from $203.29 to $203.99 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Row 5 · 2026-10-05 · Sale · Disposed 290 · Balance 563,248 F1: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on June 15, 2026. F6: Represents the weighted average sales price per share. The shares sold at prices ranging from $204.33 to $205.32 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Row 6 · 2026-10-05 · Sale · Disposed 297 · Balance 562,951 F1: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on June 15, 2026. F7: Represents the weighted average sales price per share. The shares sold at prices ranging from $205.37 to $206.34 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Row 7 · 2026-10-05 · Sale · Disposed 146 · Balance 562,805 F1: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on June 15, 2026. F8: Represents the weighted average sales price per share. The shares sold at prices ranging from $206.38 to $207.33 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Row 8 · 2026-10-05 · Sale · Disposed 45 · Balance 562,760 F1: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on June 15, 2026. F9: Represents the weighted average sales price per share. The shares sold at prices ranging from $207.38 to $207.8 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $23.33 · Expires 2029-10-23 | Direct | 131,290 |
Reported balance
Holding disclosure · report date 2026-10-05 · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · Balance 131,290 F10: 25% of the shares subject to the option vested on October 24, 2020, and 1/48th of the shares subject to the option vest on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $67.85 · Expires 2030-08-31 | Direct | 64,950 |
Reported balance
Holding disclosure · report date 2026-10-05 · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · Balance 64,950 F11: Represents performance stock options granted to the reporting person on September 1, 2020, that vested and became exercisable on December 19, 2022 as a result of the reporting person having met the applicable performance criteria. |
Filing footnotes · ownership attribution and instrument terms
F1: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on June 15, 2026.
F2: Represents the weighted average sales price per share. The shares sold at prices ranging from $200 to $200.99 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
F3: Represents the weighted average sales price per share. The shares sold at prices ranging from $201 to $201.99 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
F4: Represents the weighted average sales price per share. The shares sold at prices ranging from $202 to $202.99 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
F5: Represents the weighted average sales price per share. The shares sold at prices ranging from $203.29 to $203.99 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
F6: Represents the weighted average sales price per share. The shares sold at prices ranging from $204.33 to $205.32 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
F7: Represents the weighted average sales price per share. The shares sold at prices ranging from $205.37 to $206.34 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
F8: Represents the weighted average sales price per share. The shares sold at prices ranging from $206.38 to $207.33 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
F9: Represents the weighted average sales price per share. The shares sold at prices ranging from $207.38 to $207.8 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
F10: 25% of the shares subject to the option vested on October 24, 2020, and 1/48th of the shares subject to the option vest on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date.
F11: Represents performance stock options granted to the reporting person on September 1, 2020, that vested and became exercisable on December 19, 2022 as a result of the reporting person having met the applicable performance criteria.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 05, 2026 Filed Oct 7, 2026 20:05 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 45 | $207.46 | $9,335.50 |
DisclosureSEC source: 0001214659-26-012647 · marketforms-74107.xml · nonDerivative · entry 8 Leproust Emily M. · CIK 0001753655 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 562,760 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on June 15, 2026. F9 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $207.38 to $207.8 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| October 05, 2026 Filed Oct 7, 2026 20:05 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 146 | $206.84 | $30,199.36 |
DisclosureSEC source: 0001214659-26-012647 · marketforms-74107.xml · nonDerivative · entry 7 Leproust Emily M. · CIK 0001753655 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 562,805 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on June 15, 2026. F8 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $206.38 to $207.33 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| October 05, 2026 Filed Oct 7, 2026 20:05 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 297 | $205.78 | $61,115.83 |
DisclosureSEC source: 0001214659-26-012647 · marketforms-74107.xml · nonDerivative · entry 6 Leproust Emily M. · CIK 0001753655 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 562,951 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on June 15, 2026. F7 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $205.37 to $206.34 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| October 05, 2026 Filed Oct 7, 2026 20:05 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 290 | $204.80 | $59,391.88 |
DisclosureSEC source: 0001214659-26-012647 · marketforms-74107.xml · nonDerivative · entry 5 Leproust Emily M. · CIK 0001753655 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 563,248 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on June 15, 2026. F6 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $204.33 to $205.32 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| October 05, 2026 Filed Oct 7, 2026 20:05 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 432 | $203.61 | $87,958.31 |
DisclosureSEC source: 0001214659-26-012647 · marketforms-74107.xml · nonDerivative · entry 4 Leproust Emily M. · CIK 0001753655 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 563,538 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on June 15, 2026. F5 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $203.29 to $203.99 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| October 05, 2026 Filed Oct 7, 2026 20:05 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 1,017 | $202.32 | $205,763.10 |
DisclosureSEC source: 0001214659-26-012647 · marketforms-74107.xml · nonDerivative · entry 3 Leproust Emily M. · CIK 0001753655 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 563,970 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on June 15, 2026. F4 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $202 to $202.99 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| October 05, 2026 Filed Oct 7, 2026 20:05 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 481 | $201.26 | $96,803.94 |
DisclosureSEC source: 0001214659-26-012647 · marketforms-74107.xml · nonDerivative · entry 2 Leproust Emily M. · CIK 0001753655 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 564,987 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on June 15, 2026. F3 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $201 to $201.99 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| October 05, 2026 Filed Oct 7, 2026 20:05 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 1,840 | $200.44 | $368,805.74 |
DisclosureSEC source: 0001214659-26-012647 · marketforms-74107.xml · nonDerivative · entry 1 Leproust Emily M. · CIK 0001753655 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 565,468 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on June 15, 2026. F2 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $200 to $200.99 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| October 02, 2026 Filed Oct 5, 2026 20:05 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 45,736 | $188.88 | $8,638,798.62 |
DisclosureSEC source: 0001214659-26-012551 · marketforms-74087.xml · nonDerivative · entry 2 Leproust Emily M. · CIK 0001753655 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 567,308 F2 · shares: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. Read SEC document |
| October 01, 2026 Filed Oct 5, 2026 20:05 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 655 | $200.00 | $131,000.00 |
DisclosureSEC source: 0001214659-26-012551 · marketforms-74087.xml · nonDerivative · entry 1 Leproust Emily M. · CIK 0001753655 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 613,044 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on June 15, 2026. Read SEC document |
| September 24, 2026 Filed Sep 25, 2026 20:05 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 83 | $184.60 | $15,322.05 |
DisclosureSEC source: 0001214659-26-011980 · marketforms-74041.xml · nonDerivative · entry 10 Leproust Emily M. · CIK 0001753655 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 613,699 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on June 15, 2026. F11 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $184.33 to $184.96 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| September 24, 2026 Filed Sep 25, 2026 20:05 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 501 | $183.76 | $92,065.81 |
DisclosureSEC source: 0001214659-26-011980 · marketforms-74041.xml · nonDerivative · entry 9 Leproust Emily M. · CIK 0001753655 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 613,782 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on June 15, 2026. F10 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $183.28 to $184.25 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| September 24, 2026 Filed Sep 25, 2026 20:05 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 16 | $182.50 | $2,920.00 |
DisclosureSEC source: 0001214659-26-011980 · marketforms-74041.xml · nonDerivative · entry 8 Leproust Emily M. · CIK 0001753655 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 614,283 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on June 15, 2026. F9 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $182.25 to $183.03 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| September 24, 2026 Filed Sep 25, 2026 20:05 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 21 | $181.45 | $3,810.49 |
DisclosureSEC source: 0001214659-26-011980 · marketforms-74041.xml · nonDerivative · entry 7 Leproust Emily M. · CIK 0001753655 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 614,299 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on June 15, 2026. F8 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $181.23 to $181.61 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| September 24, 2026 Filed Sep 25, 2026 20:05 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 515 | $180.39 | $92,901.42 |
DisclosureSEC source: 0001214659-26-011980 · marketforms-74041.xml · nonDerivative · entry 6 Leproust Emily M. · CIK 0001753655 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 614,320 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on June 15, 2026. F7 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $180.23 to $181.13 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| September 24, 2026 Filed Sep 25, 2026 20:05 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 143 | $179.93 | $25,730.43 |
DisclosureSEC source: 0001214659-26-011980 · marketforms-74041.xml · nonDerivative · entry 5 Leproust Emily M. · CIK 0001753655 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 614,835 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on June 15, 2026. F6 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $179.23 to $180.21 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| September 24, 2026 Filed Sep 25, 2026 20:05 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 330 | $178.67 | $58,960.54 |
DisclosureSEC source: 0001214659-26-011980 · marketforms-74041.xml · nonDerivative · entry 4 Leproust Emily M. · CIK 0001753655 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 614,978 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on June 15, 2026. F5 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $178.1 to $179 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| September 24, 2026 Filed Sep 25, 2026 20:05 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 164 | $177.17 | $29,055.86 |
DisclosureSEC source: 0001214659-26-011980 · marketforms-74041.xml · nonDerivative · entry 3 Leproust Emily M. · CIK 0001753655 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 615,308 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on June 15, 2026. F4 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $177.05 to $177.4 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| September 24, 2026 Filed Sep 25, 2026 20:05 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 945 | $176.39 | $166,690.16 |
DisclosureSEC source: 0001214659-26-011980 · marketforms-74041.xml · nonDerivative · entry 2 Leproust Emily M. · CIK 0001753655 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 615,472 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on June 15, 2026. F3 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $176 to $176.99 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| September 24, 2026 Filed Sep 25, 2026 20:05 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 2,485 | $175.23 | $435,449.78 |
DisclosureSEC source: 0001214659-26-011980 · marketforms-74041.xml · nonDerivative · entry 1 Leproust Emily M. · CIK 0001753655 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 616,417 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on June 15, 2026. F2 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $175 to $175.99 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| September 21, 2026 Filed Sep 23, 2026 20:07 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 1,687 | $165.49 | $279,183.32 |
DisclosureSEC source: 0001214659-26-011914 · marketforms-74031.xml · nonDerivative · entry 1 Leproust Emily M. · CIK 0001753655 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 618,902 F1 · shares: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. Read SEC document |
| September 17, 2026 Filed Sep 21, 2026 20:05 UTC | Twist Bioscience Corp TWST · Entity 3619 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 133,269 | $0.00 Strike: $26.66 | $0.00 |
DisclosureSEC source: 0001214659-26-011832 · marketforms-74024.xml · derivative · entry 20 Leproust Emily M. · CIK 0001753655 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 133,269 shares Expires 2028-11-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F19 · derivative.exercise_date: The option is immediately exercisable. 20% of the shares subject to the option vested and became exercisable on October 31, 2019 and 1/60th of the shares subject to the option vested and became exercisable on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date. Read SEC document |
| September 17, 2026 Filed Sep 21, 2026 20:05 UTC | Twist Bioscience Corp TWST · Entity 3619 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 75,439 | $0.00 Strike: $8.82 | $0.00 |
DisclosureSEC source: 0001214659-26-011832 · marketforms-74024.xml · derivative · entry 19 Leproust Emily M. · CIK 0001753655 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 75,439 shares Expires 2027-09-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F18 · derivative.exercise_date: The option is immediately exercisable. 10% of the shares subject to the option vested on September 28, 2017, 15% of the shares subject to the option vested on September 28, 2018, and 1/48th of the shares subject to the option vest on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date. Read SEC document |
| September 17, 2026 Filed Sep 21, 2026 20:05 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 869 | $163.39 | $141,988.17 |
DisclosureSEC source: 0001214659-26-011832 · marketforms-74024.xml · nonDerivative · entry 15 Leproust Emily M. · CIK 0001753655 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 620,589 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on June 15, 2026. F14 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $163.03 to $163.6 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| September 17, 2026 Filed Sep 21, 2026 20:05 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 2,565 | $162.31 | $416,334.38 |
DisclosureSEC source: 0001214659-26-011832 · marketforms-74024.xml · nonDerivative · entry 14 Leproust Emily M. · CIK 0001753655 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 621,458 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on June 15, 2026. F13 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $162.02 to $163 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| September 17, 2026 Filed Sep 21, 2026 20:05 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 11,169 | $161.49 | $1,803,715.32 |
DisclosureSEC source: 0001214659-26-011832 · marketforms-74024.xml · nonDerivative · entry 13 Leproust Emily M. · CIK 0001753655 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 624,023 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on June 15, 2026. F12 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $161.00 to $161.97 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| September 17, 2026 Filed Sep 21, 2026 20:05 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 14,493 | $160.44 | $2,325,245.33 |
DisclosureSEC source: 0001214659-26-011832 · marketforms-74024.xml · nonDerivative · entry 12 Leproust Emily M. · CIK 0001753655 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 635,192 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on June 15, 2026. F11 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $160.00 to $160.99 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| September 17, 2026 Filed Sep 21, 2026 20:05 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 23,884 | $159.53 | $3,810,250.35 |
DisclosureSEC source: 0001214659-26-011832 · marketforms-74024.xml · nonDerivative · entry 11 Leproust Emily M. · CIK 0001753655 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 649,685 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on June 15, 2026. F10 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $158.99 to $159.99 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| September 17, 2026 Filed Sep 21, 2026 20:05 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 232,173 | $158.09 | $36,703,672.35 |
DisclosureSEC source: 0001214659-26-011832 · marketforms-74024.xml · nonDerivative · entry 10 Leproust Emily M. · CIK 0001753655 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 673,569 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on June 15, 2026. F9 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $157.97 to $158.96 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| September 17, 2026 Filed Sep 21, 2026 20:05 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 32,260 | $157.49 | $5,080,498.36 |
DisclosureSEC source: 0001214659-26-011832 · marketforms-74024.xml · nonDerivative · entry 9 Leproust Emily M. · CIK 0001753655 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 905,742 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on June 15, 2026. F8 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $156.96 to $157.96 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| September 17, 2026 Filed Sep 21, 2026 20:05 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 9,097 | $156.47 | $1,423,383.94 |
DisclosureSEC source: 0001214659-26-011832 · marketforms-74024.xml · nonDerivative · entry 8 Leproust Emily M. · CIK 0001753655 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 938,002 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on June 15, 2026. F7 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $155.92 to $156.91 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| September 17, 2026 Filed Sep 21, 2026 20:05 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 13,378 | $155.46 | $2,079,701.07 |
DisclosureSEC source: 0001214659-26-011832 · marketforms-74024.xml · nonDerivative · entry 7 Leproust Emily M. · CIK 0001753655 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 947,099 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on June 15, 2026. F6 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $154.9 to $155.9 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| September 17, 2026 Filed Sep 21, 2026 20:05 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 4,175 | $154.17 | $643,661.00 |
DisclosureSEC source: 0001214659-26-011832 · marketforms-74024.xml · nonDerivative · entry 6 Leproust Emily M. · CIK 0001753655 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 960,477 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on June 15, 2026. F5 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $153.88 to $154.84 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| September 17, 2026 Filed Sep 21, 2026 20:05 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 3,399 | $153.40 | $521,417.14 |
DisclosureSEC source: 0001214659-26-011832 · marketforms-74024.xml · nonDerivative · entry 5 Leproust Emily M. · CIK 0001753655 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 964,652 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on June 15, 2026. F4 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $152.87 to $153.85 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| September 17, 2026 Filed Sep 21, 2026 20:05 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 6,644 | $152.21 | $1,011,291.21 |
DisclosureSEC source: 0001214659-26-011832 · marketforms-74024.xml · nonDerivative · entry 4 Leproust Emily M. · CIK 0001753655 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 968,051 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on June 15, 2026. F3 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $151.78 to $152.71 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| September 17, 2026 Filed Sep 21, 2026 20:05 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 2,440 | $151.46 | $369,565.57 |
DisclosureSEC source: 0001214659-26-011832 · marketforms-74024.xml · nonDerivative · entry 3 Leproust Emily M. · CIK 0001753655 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 974,695 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on June 15, 2026. F2 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $150.77 to 151.77 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| September 17, 2026 Filed Sep 21, 2026 20:05 UTC | Twist Bioscience Corp TWST · Entity 3619 | Exercise / conversionCommon Stock | 75,439 | $8.82 | $665,371.98 |
DisclosureSEC source: 0001214659-26-011832 · marketforms-74024.xml · nonDerivative · entry 2 Leproust Emily M. · CIK 0001753655 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 977,135 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on June 15, 2026. Read SEC document |
| September 17, 2026 Filed Sep 21, 2026 20:05 UTC | Twist Bioscience Corp TWST · Entity 3619 | Exercise / conversionCommon Stock | 133,269 | $26.66 | $3,552,951.54 |
DisclosureSEC source: 0001214659-26-011832 · marketforms-74024.xml · nonDerivative · entry 1 Leproust Emily M. · CIK 0001753655 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 901,696 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on June 15, 2026. Read SEC document |
| September 08, 2026 Filed Sep 10, 2026 20:00 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 2,302 | $122.62 | $282,280.45 |
DisclosureSEC source: 0001214659-26-011556 · marketforms-73972.xml · nonDerivative · entry 1 Leproust Emily M. · CIK 0001753655 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 768,427 F1 · shares: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. Read SEC document |
| August 25, 2026 Filed Aug 27, 2026 20:05 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 1,093 | $154.45 | $168,809.48 |
DisclosureSEC source: 0001214659-26-010968 · marketforms-73903.xml · nonDerivative · entry 5 Leproust Emily M. · CIK 0001753655 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 770,729 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on May 27, 2025. F6 · shares: Represents the weighted average sales price per share. The shares sold at prices ranging from $154.34 to $154.64 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| August 25, 2026 Filed Aug 27, 2026 20:05 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 9,181 | $153.93 | $1,413,203.79 |
DisclosureSEC source: 0001214659-26-010968 · marketforms-73903.xml · nonDerivative · entry 4 Leproust Emily M. · CIK 0001753655 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 771,822 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on May 27, 2025. F5 · shares: Represents the weighted average sales price per share. The shares sold at prices ranging from $153.34 to $154.33 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| August 25, 2026 Filed Aug 27, 2026 20:05 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 6,412 | $152.75 | $979,433.00 |
DisclosureSEC source: 0001214659-26-010968 · marketforms-73903.xml · nonDerivative · entry 3 Leproust Emily M. · CIK 0001753655 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 781,003 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on May 27, 2025. F4 · shares: Represents the weighted average sales price per share. The shares sold at prices ranging from $152.33 to $153.32 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| August 25, 2026 Filed Aug 27, 2026 20:05 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 12,236 | $151.36 | $1,851,979.78 |
DisclosureSEC source: 0001214659-26-010968 · marketforms-73903.xml · nonDerivative · entry 2 Leproust Emily M. · CIK 0001753655 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 787,415 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on May 27, 2025. F3 · shares: Represents the weighted average sales price per share. The shares sold at prices ranging from $151.00 to $151.97 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| August 25, 2026 Filed Aug 27, 2026 20:05 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 12,648 | $150.56 | $1,904,333.47 |
DisclosureSEC source: 0001214659-26-010968 · marketforms-73903.xml · nonDerivative · entry 1 Leproust Emily M. · CIK 0001753655 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 799,651 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on May 27, 2025. F2 · shares: Represents the weighted average sales price per share. The shares sold at prices ranging from $150.00 to $150.99 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| August 21, 2026 Filed Aug 25, 2026 20:05 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 6,639 | $139.07 | $923,259.17 |
DisclosureSEC source: 0001214659-26-010828 · marketforms-73880.xml · nonDerivative · entry 1 Leproust Emily M. · CIK 0001753655 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 812,299 F1 · shares: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. Read SEC document |
| August 12, 2026 Filed Aug 14, 2026 20:05 UTC | Twist Bioscience Corp TWST · Entity 3619 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 19,952 | $0.00 Strike: $26.66 | $0.00 |
DisclosureSEC source: 0001214659-26-010403 · marketforms-73765.xml · derivative · entry 7 Leproust Emily M. · CIK 0001753655 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 133,269 Underlying: Common Stock · 19,952 shares Expires 2028-11-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: 20% of the shares subject to the option vested and became exercisable on October 31, 2019 and 1/60th of the shares subject to the option vest and become exercisable on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date. Read SEC document |
| August 12, 2026 Filed Aug 14, 2026 20:05 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 19,952 | $125.08 | $2,495,508.37 |
DisclosureSEC source: 0001214659-26-010403 · marketforms-73765.xml · nonDerivative · entry 2 Leproust Emily M. · CIK 0001753655 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 818,938 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on May 27, 2025. F2 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $125.00 to $125.25 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| August 12, 2026 Filed Aug 14, 2026 20:05 UTC | Twist Bioscience Corp TWST · Entity 3619 | Exercise / conversionCommon Stock | 19,952 | $26.66 | $531,920.32 |
DisclosureSEC source: 0001214659-26-010403 · marketforms-73765.xml · nonDerivative · entry 1 Leproust Emily M. · CIK 0001753655 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 838,890 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on May 27, 2025. Read SEC document |
| August 10, 2026 Filed Aug 12, 2026 20:05 UTC | Twist Bioscience Corp TWST · Entity 3619 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 113,318 | $0.00 Strike: $26.66 | $0.00 |
DisclosureSEC source: 0001214659-26-009994 · marketforms-73750.xml · derivative · entry 7 Leproust Emily M. · CIK 0001753655 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 153,221 Underlying: Common Stock · 113,318 shares Expires 2028-11-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: 20% of the shares subject to the option vested and became exercisable on October 31, 2019 and 1/60th of the shares subject to the option vest and become exercisable on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date. Read SEC document |
| August 10, 2026 Filed Aug 12, 2026 20:05 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 113,318 | $125.16 | $14,183,050.86 |
DisclosureSEC source: 0001214659-26-009994 · marketforms-73750.xml · nonDerivative · entry 2 Leproust Emily M. · CIK 0001753655 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 818,938 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on May 27, 2025. F2 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $125.00 to $125.51 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.